Recommended

Download our FREE report – Beyond the Lab: Stem cell research
The future of carcinogenicity risk assessment: AI-powered, ethical alternatives to traditional testing, explore this new webinar and register now!
The rise of organoids: a new era in drug discovery, this webinar is coming in March and we are excited for you to join! Register now!
Secure your place at this exciting upcoming webinar on advancing obesity drug discovery! Register now.
Webinar

The future of carcinogenicity risk assessment: AI-powered, ethical alternatives to traditional testing

2 April 2025

3:00pm

Explore how a Weight of Evidence (WoE) approach uses in vitro methods and artificial intelligence (AI) to transform carcinogenicity risk assessment, reducing reliance on animal studies while enhancing compliance with FDA and ICH guidelines.

The FDA ICH S1B (R1) guidance introduces a Weight of Evidence (WoE) approach for assessing human carcinogenic risk in drug development, aiming to replace traditional two-year rat carcinogenicity studies. This innovative framework integrates data from diverse sources, including in vitro, animal, and clinical studies, while focusing on six key WoE factors: target biology, secondary pharmacology, chronic histopathology, hormonal perturbation, genotoxicity, and immune modulation. Together, these factors offer a comprehensive and interconnected perspective on carcinogenic risk.

In this webinar, discover how Eurofins Discovery has developed a comprehensive WoE platform using advanced in vitro methods. Key innovations include molecular target evaluations to detect non-genotoxic carcinogens, nuclear hormone receptor panels for assessing hormonal perturbation, and genotoxicity assays such as ames and micronucleus tests. Plus, find out how cutting-edge BioMAP technology provides insights into immune and hormonal safety profiles, while an AI-driven cell transformation assay (CTA) evaluates carcinogen-induced malignant phenotypes with precision.

Results demonstrate that the carcinogenicity risk assessment panel effectively identifies diverse carcinogens and their mechanisms. AI-enhanced image analysis in the Bhas 42 CTA boosts efficiency and objectivity. This approach enables early detection of carcinogenic liabilities, aligns with ICH S1B(R1) guidelines, and offers a humane, streamlined alternative to traditional two-year rat studies.

Key learning points:

  • Understand the Weight of Evidence (WoE) approach and its role in modern carcinogenicity risk assessment.
  • Explore the six critical WoE factors that provide comprehensive insights into carcinogenic risks.
  • Discover innovative in vitro alternatives to animal testing for ethical and efficient drug development.
  • Learn about AI-assisted Cell Transformation Assays (CTA).
  • Gain insights into identifying carcinogenic mechanisms.
  • Adopt a cost-effective and ethical strategy that aligns with regulatory guidelines while advancing drug safety.

Register now to secure your place>>>

SPEAKER

Jase Hsu

Dr. Jace Hsu – Technical Manager, Eurofins Panlabs Discovery Services

Dr. Jace Hsu is a seasoned pharmacology expert with over 20 years of pharmaceutical R&D experience. Holding a PhD in pharmacology, he has led drug development projects in the CNS, inflammatory, and metabolism fields for six years. At Eurofins Discovery, Dr. Hsu provides consultative support and technical expertise.

FAQs

Is the webinar free?
Yes – there is no charge to watch the webinar, either live or on-demand.

When will the webinar take place?
The webinar will take place live on 2 April 2025 at 3PM GMT. 

I’m busy. Can I watch it later?
The webinar will become available to watch on-demand shortly after the live webinar takes place.

What are the benefits of attending live?
During the live webinar, you’ll be able to ask the speakers your questions, which will then be answered during the live Q&A session towards the end of the webinar.

How long will the webinar be?
This webinar will last for up to one hour.

What do I need to watch this webinar?
All you need is a computer with an internet connection. Be sure to use headphones if in an office environment.

Do I receive a certificate?
Yes, you will receive a certificate if you attend the webinar live. The certificate will be sent with your on-demand video link.